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Abstract 
 
Background and aims: The functional gastrointestinal disorders (FGIDs), are 
extremely common conditions associated with a considerable personal, social and 
health economic burden. Managing FGIDs in clinical practice is challenging because 
of the uncertainty of symptom-based diagnosis, the high frequency of overlap 
between these conditions and the limited efficacy of available therapies. It has often 
been argued that successful drug development and management of FGIDs requires 
knowledge of the underlying pathophysiology. Numerous and highly variable 
candidate pathophysiological mechanisms have been implicated in the generation of 
FGID symptoms, but there is no current consensus on how to best define the 
relevance of these disturbances. Methods: A group of international experts on FGIDs 
developed plausibility criteria that should be fulfilled by relevant pathophysiological 
mechanisms in FGIDs. Results: Five criteria are proposed: 1) presence of the 
abnormality in a subset of patients; 2) temporal association between proposed 
mechanism and symptom(s); 3) correlation between the level of impairment of the 
mechanism and symptom(s); 4) induction of the symptom(s) by provoking the 
pathophysiological abnormality in healthy subjects and 5) treatment response by a 
therapy specifically correcting the underlying disorder, or congruent natural history of 
symptoms and dysfunction in the absence of specific therapy. Based on strength of 
evidence for these 5 criteria, a plausibility score is proposed. Conclusion: Evaluation 
of the strength of evidence for candidate pathophysiological abnormalities fulfilling 
these 5 plausibility criteria will help to identify the most relevant mechanisms to target 
for novel diagnostic approaches and for the development of new therapies. 
 
Keywords: functional gastrointestinal disorders, pathophysiological mechanisms, 
gastrointestinal motility, gastroesophageal reflux, visceral hypersensitivity, plausibility 
criteria 
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Summary box 
What is already known about this subject: 
 Several pathophysiological mechanisms have been implicated in the 
generation of functional gastrointestinal disorders 
 Variable arguments to support the relevance of individual candidate 
pathophysiological mechanisms 
 No standard set of requirements has been defined that would establish the 
relevance of an individual candidate pathophysiological mechanism 
What are the new findings:  
 A group of international experts developed plausibility criteria for mechanisms 
in functional gastrointestinal disorders 
 These are based on aspects such as presence, temporal association, 
correlation between level of impairment and symptom severity, induction in 
healthy subjects and treatment response or congruent natural history 
 The plausibility criteria were applied to 4 specific mechanisms in 3 different 
functional disorders 
How might it impact on clinical practice in the foreseeable future? 
 Evaluation of plausibility criteria allows 1) to summarize current knowledge, 2) 
to identify gaps requiring targeted future research and 3) may help to advance 
the field of functional gastrointestinal disorders 
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1. Introduction. 
 
Functional gastrointestinal disorders (FGIDs) are characterized by the presence of a 
variety of chronic, typically episodic symptoms attributed to the gastrointestinal tract in 
the absence of an underlying histological, biochemical, or physiological mechanism 
that consistently explains the symptoms (1). FGIDs may be characterized by 
symptoms that are attributable to the pharynx, esophagus, stomach, biliary tract, 
small intestine, colon or anorectum, and their pathogenesis has remained obscure 
(1). However, over the last two decades, it has become clear that a significant 
proportion of FGIDs are associated with at least one pathophysiological abnormality, 
each being observed in 25 to 40% of the patients. Thus, a number of putative 
pathophysiological mechanisms have been proposed, including disordered motility, 
visceral hypersensitivity, low-grade inflammation, altered microbiota, immune 
activation, adverse reactions to foods and central nervous system dysfunction (which 
may or may not be related to psychological dysfunction) (2-6).  
 
Despite the fact that these disturbances have been reported in patients with FGIDs, 
their relevance to symptom generation remains the subject of debate, in part because 
of the absence of a clearly established causal or even temporal relationship between 
symptoms and observed abnormal function, as well as the inadequacy of medications 
to specifically target the putative underlying mechanisms.  
 
Several cross-sectional studies attempting to correlate symptoms with 
pathophysiological mechanisms in FGIDs have been criticized because they failed to 
explain a given symptom in all patients, or because of an inability to rule out other 
contributing mechanisms (7-10). This controversy reflects a number of specific 
problems associated with FGIDs. In functional syndromes, the assessment of the 
nature and the severity of symptoms is currently dependent on patient self-reports. In 
addition, it is often assumed that FGIDs consist of subgroups with heterogeneous 
symptoms and different underlying pathophysiology (11-13).  
 
2. The case of heartburn and gastro-esophageal reflux of acid. 
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To illustrate the concept of developing criteria to establish relationships between 
pathophysiological mechanism(s) and gastrointestinal disorders, let us consider the 
role of acid gastro-esophageal reflux in the pathophysiology of heartburn. The broad 
acceptance of this mechanism of symptom generation as being causal is based on 
several observations: first, the finding of increased esophageal acid exposure on pH 
monitoring in patients with heartburn (“presence”); second, the temporal association 
between reflux events and heartburn occurrence (“temporal association”); third, the 
worsening of heartburn scores with increasing severity of esophageal acid exposure 
(“correlation”); fourth, the induction of heartburn by esophageal acid perfusion 
(“induction”) and fifth, the response of symptoms to acid-suppressive therapy 
(“treatment response”) (14). The pathophysiological relevance of acid reflux for 
heartburn symptom generation is well established in spite of the fact that not all 
heartburn can be attributed to (acid) reflux, with these patients being referred to as 
having functional heartburn (14,15). Conversely, not all subjects with increased 
esophageal acid exposure experience symptoms of heartburn (16), indicating that 
100% correlation is not considered necessary. 
 
To date, no criteria have been proposed to establish plausibility for a causal 
relationship between a pathophysiological mechanism and one or more symptoms in 
FGIDs. In infectious disease, for instance, Koch’s postulates are well-accepted, 
representing rigorous criteria that link infectious diseases to specific microbial 
infectious agents (17). Similarly, the Bradford Hill criteria are a group of criteria that 
provide evidence of a causal relationship between a putative risk factor and a possible 
consequence in epidemiology research (18). Research on pathophysiological 
mechanisms of FGIDs may benefit and gain focus if a similar set of standards could 
be proposed. 
 
The aim of this paper is to develop a set of standards to be used as criteria for 
qualifying putative pathophysiological mechanisms as relevant to the symptoms and 
management of patients with FGIDs.  
 
3. Consensus development process. 
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The decision to initiate a consensus effort to establish plausibility of mechanisms 
underlying FGID symptom generation was taken by a small core group (JT, MS, HT, 
LVO) that prepared and initiated the process after a meeting in Gothenburg in August 
2014. As the issue of plausibility criteria for pathophysiological mechanisms has no 
existing precedent efforts, and is not readily amenable to traditional scientific 
investigation, an approach based on expert-based consensus was chosen (19). The 
core group identified a group of eligible contributors, with a well-established track 
record in studying FGID pathophysiology, who were selected and invited to participate 
in the process. The selection process took into account 1) diversity in pathophysiology 
research expertise (gastrointestinal motility, visceral hypersensitivity, microbiota, 
psychosocial co-morbidities, central nervous system processes), 2) focus on specific 
parts of the GI tract (esophagus, stomach, bowel), 3) affiliations with different 
societies (UEG, AGA, WGO, European, American and Asian-Pacific Motility societies) 
and 4) region. All invited participants agreed to participate and were supportive of the 
scope and general aims of the project, leading to the consensus group comprising the 
current 9 members. 
 
The core group drafted a number of plausibility criteria which were described in a 
working document. Face-to-face interactions of (subgroups of) participants occurred 
at international conferences in 2014 and 2015. These interactions served to adapt, 
expand or decrease the list of plausibility criteria based on full consensus, and to 
generate a list of mechanisms and conditions to be considered for illustrative analysis. 
These included diverse organ systems and candidate pathophysiological 
mechanisms. Proposed topics included esophageal hypersensitivity in functional 
heartburn and non-cardiac chest pain, reflux in non-cardiac chest pain, gastric 
emptying in functional dyspepsia (FD), impaired gastric accommodation in FD, H. 
pylori infection in FD, gastric hypersensitivity in FD, increased mucosal permeability in 
the irritable bowel syndrome (IBS), transit disorders in IBS, rectal hypersensitivity in 
IBS, altered microbiota in IBS and stress and anxiety in FD or IBS, amongst others.  
 
The consensus process generated a final list of 6 different plausibility criteria, and 
selected 5 combinations of pathophysiological mechanisms and FGIDs for potential 
illustrative analysis. The members of the consensus group drafted different text 
segments which were merged into a first draft of the manuscript which was circulated 
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amongst all participants in the Summer of 2015. All members commented on content 
and wording, and areas of disagreement were identified, discussed and, if needed, 
adapted. This process resulted in an optimization of the plausibility criteria wording, a 
restructuring of the criteria into 5 categories (one with two components) and an 
ongoing discussion on the number of illustrative analyses to be included. An updated 
version of the criteria was generated and circulated for evaluation early in 2016, and 
all panel members agreed in full with the current set of criteria. Based on the 
discussion, strength of evidence grading was also added to the document (20), and 
the illustrative analyses were chosen, taking into account the desire to include 
variations in type of pathophysiological mechanism and different organs of the 
gastrointestinal tract, while avoiding topics that were recently evaluated in detail in the 
literature (21). Revisions throughout 2016 led to finalization of the current document. 
 
4. Criteria linking symptoms and mechanisms in functional gastrointestinal 
disorders. 
 
Based on the case of heartburn and acid reflux, a number of “criteria” can be put 
forward that add weight to accepting a causal relationship between a 
pathophysiological mechanism and a (functional) gastrointestinal symptom. These 
include presence of the mechanism in at least a subset (if not all) of the subjects with 
the symptom (criterion 1: “presence”), a temporal association between the presence 
of the mechanism and symptom occurrence (criterion 2: “temporal association”); a 
correlation between the level of impairment of the mechanism and the severity of the 
symptom, which is usually cross-sectional (criterion 3: “correlation”); induction of the 
symptom by inducing the pathophysiological abnormality  in asymptomatic subjects 
(criterion 4: “induction”); and, finally, a favorable response to a treatment aimed at 
specifically correcting the underlying pathophysiological mechanism (“criterion 5: 
treatment response”) (Table 1). In the absence of a specific therapeutic intervention, 
observations of congruent evolution over time between the severity of the symptom 
and the severity of the pathophysiological mechanism (criterion 5b: “congruent natural 
history”) is a potential alternative approach. The strength of evidence can be 
evaluated using the GRADE system (Table 2) (20). Similar to what was pointed out 
for subjects with pathological acid exposure without heartburn symptoms, the 
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presence of a putative pathophysiological abnormality in some subjects in the 
absence of symptoms does not necessarily invalidate its relevance. 
 
In the following paragraphs, we will evaluate the extent to which four frequently 
proposed mechanisms in three common FGIDs fulfill these criteria. We chose to 
evaluate conditions in different anatomical regions of the gastrointestinal tract, and we 
selected a disorder of chemosensitivity (acid reflux in non-cardiac chest pain), two 
disorders of motility control (delayed gastric emptying and impaired gastric 
accommodation in functional dyspepsia (FD)) and a disorder of mechanosensitivity 
(colorectal hypersensitivity in IBS) as primary examples. These examples are not 
chosen because the mechanisms are unequivocally correlated with symptom(s) on all 
5 criteria. Rather, they were chosen because the published evidence illustrates some 
positive criteria, and also because they fail to fulfill some of the plausibility criteria, 
thereby identifying areas requiring future research for the validation of the putative 
mechanism. 
 
5. Relationship between symptoms and acid reflux in non-cardiac chest pain. 
 
Presence: Esophageal pH monitoring demonstrates the presence of pathological 
esophageal acid exposure in up to 62% of the patients with non-cardiac chest pain 
(22). However, even in the absence of pathological reflux, reflux can still be the cause 
of a patient’s symptoms of chest pain in patients with an acid-hypersensitive 
esophagus (23).   
Temporal association: In non-cardiac chest pain, esophageal pH monitoring with 
symptom registration shows a significant temporal association between acid reflux 
and symptom occurrence in, on average, 31% of all patients with this symptom (23).  
Correlation: In population-based studies, the prevalence of chest pain of presumed 
non-cardiac origin increased with increasing frequency of typical GERD symptoms 
(which are in turn assumed to be caused by acid reflux) (24,25). Whether the severity 
of chest pain increases with increasing acid exposure in NCCP patients has not been 
adequately assessed. 
Induction: Esophageal acid perfusion mimics symptoms in 10 to 38% of unselected 
patients with non-cardiac chest pain (22). However, there are no reports of induction 
of reflux-related chest pain in healthy volunteers. 
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Therapeutic response: Case series and controlled trials demonstrate that proton pump 
inhibitor therapy may be effective in up to 80% of patients selected for reflux-related 
non-cardiac chest pain and its empirical use for both diagnostic and therapeutic 
purposes has been advocated for this reason (22,23). 
Congruent natural history: No longitudinal follow-up studies evaluating relationships 
between acid reflux and symptoms of non-cardiac chest pain are available outside of 
the setting of interventional therapeutic trials. 
The fulfillment of criteria for association of acid reflux with non-cardiac chest pain is 
summarized in Table 3.  
 
 
6. Relationship between symptoms and impaired gastric accommodation in 
functional dyspepsia. 
 
Presence: A number of studies, using different methods, reported that meal-induced 
gastric accommodation is impaired in approximately 40% of FD patients (2).  
Temporal association: FD is increasingly considered to be a meal-related condition 
(26) and this is especially true for the subgroup referred to as the postprandial distress 
syndrome, according to the Rome III definition (27). In a large study in tertiary care, 
symptoms were triggered by ingestion of a meal in the vast majority of FD patients, 
reached a maximum early after ingestion and gradually decreased over the 4-hour 
measurement period (26). The time course of these symptoms parallels the arrival 
and presence of food in the stomach, and the process of gastric accommodation, 
which allows the proximal stomach to receive and store food. Nevertheless, other data 
suggest that some FD symptoms are also generated from the small intestine (28). 
Correlation: Studies evaluating overall FD symptom severity failed to find a significant 
impact of the presence of impaired accommodation (2,29,30). On the other hand, a 
number of studies reported associations between impaired gastric accommodation 
and the presence and severity of early satiation (31,32) or with the presence of 
unexplained weight loss (32,33), but others failed to find such association (34). Thus, 
while there is some evidence for an association with the symptoms of early satiation 
and weight loss, the severity of other symptoms of FD does not seem to be correlated 
to gastric accommodation. 
Commento [QEM1]: Should this not 
be the severity of impaired 
accommodation?  
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Induction: Impaired accommodation was induced in healthy volunteers through 
pharmacological interventions (nitric oxide synthase inhibition, motilin receptor 
agonists, opioid receptor antagonism, GLP-1 analogue) or by psychological 
manipulation (anxiety induction), and this was associated with early satiation and 
decreased nutrient volume tolerance (35-39). In contrast, administration of both the 
cannabinoid (CB)1 receptor antagonist rimonabant and of the gut peptide ghrelin 
inhibited gastric accommodation in healthy controls, while no significant difference in 
meal-induced satiation occurred but some other symptom ratings tended to increase 
(40,41). Taken together, the majority of studies showed that induction of impaired 
accommodation also induced early satiation in healthy volunteers.    
Therapeutic response: A number of drugs with the potential to enhance gastric 
accommodation have been evaluated in FD patients, but most of them have several 
additional actions and the link between symptom response and change in 
accommodation is often not assessed. A pilot study with the 5-HT1A agonist buspirone 
showed a relationship between enhancement of gastric accommodation and 
improvement of symptoms in a small group of FD patients (42). A larger multicenter 
study in Japan with tandospirone, also a 5-HT1A agonist, confirmed efficacy in FD that 
could not be attributed to the anxiolytic and antidepressant properties of the drug (43).  
Acotiamide is a novel, first-in-class drug which is an antagonist of the inhibitory 
muscarinic type 1 and type 2 (M1/M2) auto-receptors on cholinergic nerve endings, 
and is also a cholinesterase inhibitor (44). Through these actions, acotiamide 
enhances the availability of synaptically released acetylcholine, thereby enhancing 
reflex-controlled motility. In a placebo-controlled pilot study, acotiamide was superior 
in providing symptom relief in FD, and this was accompanied by enhancement of 
gastric accommodation (45). The enhancing effect of acotiamide on gastric 
accommodation was confirmed using ultrasound in a small study in Japan (46). Based 
on phase 2 and 3 studies, the drug was approved in Japan for the treatment of FD 
(47-49). However, the drug also enhances gastric emptying rate and inhibits stress-
related effects on gastric function and nutrient intake (46,50), and thus impaired 
accommodation is not necessarily the only mechanisms whereby acotiamide may 
exert its therapeutic effect. 
Congruent natural history: To our knowledge, no longitudinal follow-up studies 
assessing evolution of both symptoms and gastric accommodation in FD are 
available. 
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The criteria for association of impaired gastric accommodation with FD symptoms are 
summarized in Table 3. While some criteria are fulfilled, it is clear that there is a need 
for additional studies on the strength of the association between FD symptoms and 
impaired accommodation, and the evolution of this association, if any, over time. 
 
7. Relationship between symptoms and delayed emptying in functional 
dyspepsia. 
 
Presence: Impaired gastric emptying has been proposed as one of the underlying 
pathophysiological mechanisms in FD. Several studies reported that gastric emptying 
of a radiolabeled meal was delayed in 25 to 50% of FD patients (2). Notwithstanding 
the occurrence of delayed emptying in FD, it cannot completely account for all 
symptoms since a major proportion of patients have a normal emptying rate. 
Temporal association: Only a few studies have addressed the occurrence of FD 
symptoms in relation to gastric emptying. In a large study in tertiary care FD patients, 
symptoms were triggered by ingestion of a meal in the vast majority of patients, 
reached a maximum early after ingestion and gradually decreased over the 4-hour 
measurement period (26). While the time course of these symptoms parallels the 
presence and emptying of food from the stomach, a recent study also provided 
evidence that some FD symptoms are also likely to be generated from the small 
intestine given their time course relative to meal ingestion (51). 
Severity correlation: Several studies have evaluated the relationship between delayed 
gastric emptying and FD symptom pattern and severity. While smaller sized studies 
failed to find an association, a number of studies which included more than 300 
patients found associations between delayed emptying and the symptoms 
postprandial fullness, nausea or vomiting (2,52-55). These large-scale studies 
reported higher prevalence rates for specific symptoms in FD patients with delayed 
emptying compared to those with normal emptying. The correlation between the 
severity of these symptoms and the degree of delayed emptying was not reported in 
detail. Hence, the strength of the correlation between delayed emptying and 
dyspepsia symptom severity is understudied. 
Induction: Several studies have used nutritional, physical or pharmacological 
interventions to delay gastric emptying rates in healthy subjects, but none assessed 
the occurrence of dyspepsia-like symptoms in the participants (56-65). In a study 
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using sumatriptan as a pharmacological agent to delay gastric emptying in healthy 
subjects, no increase in meal-related symptoms was induced (66). 
Therapeutic response: Gastroprokinetic drugs (such as cisapride, domperidone, 
erythromycin and tegaserod), have been extensively evaluated in clinical trials in FD 
patients. In meta-analyses of the published literature, prokinetics were superior to 
placebo in providing relief of FD symptoms, but there were indications of publication 
bias with omissions of negative trials (67). Furthermore, the symptomatic benefit of 
prokinetics was poorly correlated to their effect on gastric emptying rate (68), 
suggesting that effects of these drugs on gastric accommodation, sensitivity to gastric 
distention and on gastro-esophageal reflux may all contribute to the symptom impact 
in FD (69,70). In keeping with this hypothesis, large clinical trials with the potent 
prokinetic macrolide ABT-229 were unequivocally negative with regard to symptom 
improvement (71). 
Parallel evolution: To our knowledge, no longitudinal follow-up studies assessing the 
evolution of both symptoms and gastric emptying in FD are available. 
The criteria for association of delayed gastric emptying with FD symptoms are 
summarized in Table 2. While some criteria are fulfilled, it is clear that there is room 
for additional studies on the strength of the association between symptom severity 
and delayed emptying, and its evolution over time. 
 
 
8. Relationship between symptoms and colorectal hypersensitivity in the 
irritable bowel syndrome. 
 
Presence: Colorectal hypersensitivity is considered to be one the most important 
pathophysiological mechanisms in IBS Several studies have confirmed that IBS 
patients show increased sensitivity to colorectal balloon distention, while colorectal 
compliance is not altered (72-83). Colorectal hypersensitivity is present in a large 
subset of IBS patients, but it is not present in all, so it cannot account for all IBS 
symptom generation. 
Temporal association: The temporal relationship between IBS symptom generation 
and colorectal hypersensitivity is only partly established. In fact, colorectal 
hypersensitivity is often considered a marker for more generalized intestinal 
hypersensitivity, and it is thought that the entire gastrointestinal tract may contribute to 
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symptom generation (84,85). The strongest indication of a temporal association 
between colorectal sensitivity and symptoms is derived from studies of meal 
aggravation of IBS symptoms: the increase of IBS symptoms after a meal paralleled 
increased rectal sensitivity (86-88), although healthy controls were also sensitized 
after meal ingestion (89). 
Correlation: A number of large-scale studies reported associations between colorectal 
hypersensitivity and the presence and severity of abdominal pain and other symptoms 
in IBS (73,78,80,82,83), but the strength of the correlation was weak to moderate at 
best, and there are also studies that revealed no association between colorectal 
hypersensitivity and overall IBS symptom severity (75,89). In fact, psychologically 
driven severity reporting has been implicated as a confounder of assessment of 
sensitivity to colorectal distention in IBS (90,91). 
Induction: Only one group reported on induction of rectal hypersensitivity in healthy 
volunteers; in that instance by the administration of glycerol (92,93). Attempts to 
sensitize the rectum using tryptophan depletion, antagonism of endogenous opioid 
pathways or anxiety induction, were not successful (94-97). In post-hoc analysis, 
acute tryptophan depletion increased perception ratings to distention in the lower 
pressure ranges, but not in the more intense and pain-generating ranges (95). 
Nutrients induced increased rectal sensitivity and this was associated with more 
severe symptoms in IBS (86-88), and to some extent also in healthy individuals (89).  
Therapeutic response: A number of studies, generally of small size, have evaluated 
changes in colorectal sensitivity induced by drugs known to provide symptomatic 
benefit in IBS patients. The clinical efficacy of alosetron in IBS-D was not paralleled by 
a change in sensitivity thresholds to isobaric visceral distention in a separate 
mechanistic study (98,99). Similarly, the clinical efficacy of tegaserod, as well as 
lubiprostone, in IBS-C was not associated with increases in thresholds to elicit 
discomfort or pain during rectal sensitivity testing in separate smaller studies (98,100-
102). In studies of psychological therapies in IBS (cognitive-behavioral therapy or brief 
psychotherapy), symptom improvement was paralleled by improvements in visceral 
sensitivity and the same has also been found for treatment with antidepressants in 
some, but not all, studies (103-108). Moreover, use of intrarectal lidocaine has, in 
small studies, reversed rectal hypersensitivity and improved abdominal pain in 
patients with IBS (109,110). Ketotifen improved symptoms of abdominal pain in a 
controlled study in IBS, and also improved visceral hypersensitivity, but there was no 
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correlation between changes in sensory thresholds and changes in abdominal pain 
scores after treatment (111). 
Congruent natural history: Conflicting results exist regarding the evolution of colorectal 
sensitivity over time in IBS patients and its association with symptom evolution. In one 
study a small group of IBS patients (n=15) underwent rectal balloon distensions and 
GI symptom assessment on two occasions, three months apart, and a significant 
correlation between changes in IBS symptoms and rectal sensitivity was 
demonstrated (83). Another study assessed evolution of rectal sensitivity over 12 
weeks in 33 IBS patients and found that rectal sensitivity was either unchanged or 
increased in patients with stable GI symptoms (78). In contrast, a longitudinal follow-
up study applied rectal sensitivity evaluations to IBS patients and healthy controls at 
4-month intervals for one year. In this study, perceptual ratings in response to rectal 
distention returned to control levels over 12 months, whereas IBS symptom severity 
did not significantly change (112). This suggests that part of the increased sensitivity 
to rectal distention in IBS may be related to stress and anxiety related to the index 
procedure, and that repetition of the stimulus results in habituation to visceral 
distention tests.  
 
The criteria for association of colorectal hypersensitivity with IBS symptoms are 
summarized in Table 3. While some criteria are fulfilled, it is clear that there is a need 
for additional studies on the strength of the association between IBS symptoms and 
colorectal hypersensitivity, and its relevance as a therapeutic target. 
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8. Plausibility score 
 
Based on the strength of evidence as evaluated using the GRADE system (20), a 
numerical plausibility score can be constructed, by allocating a score ranging from 3 
to 0, corresponding to GRADE ratings of A to D respectively, for the first 4 criteria 
(“Presence”, “Temporal association”, “Correlation” and “Induction”). For the 5th 
criterion items (“Therapeutic response” or “Congruent natural history”), the highest of 
both is used to generate a 5th number; adding up the five numbers generates a 
plausibility score between 0 and 15. Applying these scores to the pathophysiological 
mechanisms listed in Table 3 generates plausibility scores of 11 of acid reflux in 
NCCP, of 9 for impaired accommodation in FD, of 7 for delayed emptying in FD and of 
6 for rectal hypersensitivity in IBS (Table 3). 
 
 
9. Discussion 
 
The purpose of this manuscript was to propose a number of criteria that should be 
fulfilled before a pathophysiological mechanism can be considered to be involved in 
symptom generation in a FGID. We used the well-accepted association between 
heartburn and acid reflux as the benchmark and, based on the state of knowledge on 
this association and interactions between the authors of this manuscript, we 
developed a set of 5 plausibility criteria. These include obvious aspects like criterion 
1: “presence”, criterion 2: “temporal association” and criterion 3: “correlation”, but also 
additional requirements such as criterion 4: “induction” and “criterion 5: treatment 
response”.  
 
It is probably true that most researchers already use a type of subjective plausibility 
evaluation when formulating or pursuing hypotheses, and hence many may believe 
that such a set of criteria already exists. However, no publication proposing 
plausibility criteria exists in the literature, and the interactions amongst the panel 
clarified that members had a number of plausibility criteria driving their own 
pathophysiological research. However, none of the participants alone was considering 
all criteria proposed in this manuscript, again confirming the value of the consensus 
approach.  
Commento [QEM2]: This implies 
that you could have 6 criteria. How 
about “the highest of whichever is 
deemed appropriate for that 
mechanism is used”   
Commento [MC3]: Please see my 
comments in table 3 
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There are obvious limitations to the feasibility of studying each of these criteria in the 
context of a given potential pathophysiological mechanism. For instance, induction of 
the abnormality in healthy volunteers may not always be possible, as this depends on 
the nature of the abnormality and the availability of suitable interventions to mimic it 
temporarily in an innocuous way. Treatment options considered for criterion 5 aim at 
providing symptomatic relief by correcting a pathophysiological mechanism. There are 
evident limitations to criterion 5, as suitable and selective treatment options are 
lacking. In this case, criterion 5b: “congruent natural history” may serve as a valid, 
although difficult to accomplish, alternative approach.  
 
The field of FGIDs is often approached with skepticism driven by the assumption that 
single pathophysiological mechanisms are unlikely to be relevant and that the 
underlying disease mechanisms are much more complex and defy a reductionist 
approach. Even if this would be the case, there is a clear need for a structured 
approach, to take better stock of what is currently known and plausible, to identify 
areas of uncertainty or lack of data, and to address these in future research agendas 
based on the plausibility criteria evaluation. The plausibility criteria as described here 
allow such a systematic approach. Transforming the GRADE strength of evidence 
into numbers generates a tangible numerical “plausibility score”. This allows 
comparative evaluations of strength of plausibility for different mechanisms in the 
same condition, or to compare plausibility of mechanisms across diagnostic entities. 
In the examples outlined above, the plausibility of disorders explaining a functional 
disorder is explored. However, the process may also be applied to individual 
symptoms within a functional disorder (e.g. impaired accommodation explaining early 
satiation in functional dyspepsia).  
 
Furthermore, even if FGIDs do not depend on single pathophysiological mechanisms, 
but rather occur in the presence of two or more disease mechanisms which may be 
closely related and interdependent (e.g. disordered motor and sensory function of 
stomach or rectum) or unrelated (e.g. a combination of a motor disorder with anxiety), 
the plausibility evaluation process can be applied to combinations of mechanisms as 
well. Another limitation is the well-known overlap of FGIDs, which may or may not be 
caused by common pathogenetic and pathophysiological mechanisms. The current 
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plausibility criteria are not only applicable to FGIDs as discrete entities but may 
potentially also be used to evaluate pathophysiological mechanisms underlying 
overlapping conditions. However, these latter approaches are considerably more 
complex.  
 
The four mechanisms that were evaluated in the current manuscript cover only a 
small fraction of all putative pathophysiological mechanisms implicated in the 
pathogenesis of many different FGIDs. Outside the scope of the present paper, but of 
major value would be the evaluation of plausibility as mechanisms for many diverse 
putative pathophysiological factors, such as genetic factors, environmental influences, 
trauma or abuse, increased mucosal permeability, gut microbiota, etc. Evidently, the 
number and type mechanisms that can be evaluated depend on the state of the 
science and hence, over time, seemingly well-accepted mechanisms can be dropped 
based on new data, completely new mechanisms can emerge based on scientific 
progress, and old mechanisms can regain interest based on new data or analyses. 
Scenarios and implications may differ according to the state of science, and hence 
may change over time. The numerical “plausibility strength” score should also be 
interpreted taking into account the state of knowledge and evidence. For instance, a 
low score based on a lack of studies implies that more research is needed, rather 
than that the mechanism should not be further pursued. Conversely, a situation where 
a lot of research with mostly negative findings exists argues against the plausibility of 
a mechanism.  
 
Pending future progress in the area, we propose a framework to evaluate the state of 
existing knowledge on the role of putative pathophysiological mechanisms in the 
generation of one or more symptoms in FGIDs. These plausibility criteria, which are 
easily translated into a numerical score, allow us to summarize current knowledge 
and to identify gaps requiring targeted future research, which may help to advance 
the field of FGIDs. 
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TABLES 
 
Table 1. Listing of putative criteria for implicating pathophysiological mechanisms in 
symptom generation of functional gastrointestinal disorders. 
 
Number Criterion Description 
1 “Presence” The pathophysiological disturbance is present in at least a 
subset of patients with the functional gastrointestinal 
symptom, and the prevalence is higher than in appropriate 
controls. 
2 “Temporal 
association” 
A close temporal association exists between the 
pathophysiological disturbance and the symptom occurrence 
3 “Correlation” A significant correlation exists between the 
presence/severity of the symptom and the presence and the 
severity of the disturbed function. 
4 “Induction” Inducing or mimicking the dysfunction generates the 
symptom in asymptomatic subjects. 
5 A. “Therapeutic 
response” 
Treatment aimed at correcting the underlying disorder 
improves the symptom. Or: 
B. “Congruent 
natural history” 
Changes in symptom severity parallel changes in the 
severity of the disturbance.  
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Table 2. Grade system (ref. 18) 
 
Code 
Quality of 
Evidence 
Definition 
A High 
Further research is very unlikely to change our confidence in the estimate 
of effect. 
• Several high-quality studies with consistent results 
• In special cases: one large, high-quality multi-center trial 
B Moderate 
Further research is likely to have an important impact on our confidence 
in the estimate of effect and may change the estimate. 
• One high-quality study 
• Several studies with some limitations 
C Low 
Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
• One or more studies with severe limitations 
D Very Low 
Any estimate of effect is very uncertain. 
• Expert opinion 
• No direct research evidence 
• One or more studies with very severe limitations 
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Table 3. State of fulfillment of putative criteria for implicating pathophysiological 
mechanisms in symptom generation in 3 prototype functional gastrointestinal 
disorders, based on the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) system (see Table 2).  
 
 
Number Criterion NCCP: 
acid reflux 
FD: impaired 
accommodation 
FD delayed 
gastric emptying 
IBS: rectal 
hypersensitivity 
1 Presence A A A A 
2 Temporal 
association 
A B B C 
3 Correlation A C* C** C*** 
4 Induction D B D D 
5 A. Therapeutic 
response 
B C C C 
B. Congruent 
natural 
history 
D D D D 
Plausibility score**** 11 9 7 6 
 
* Only supportive data for early satiation and weight loss. 
** Only support for postprandial fullness, nausea and vomiting in selected studies 
*** A majority of studies found correlations, but they are often in the weak to moderate 
range and relate to a single symptom or a subset of symptoms. 
**** This score is generated by allocating numbers ranging from 3 to 0 for GRADE 
scores A to D respectively for each of the 4 items and for the highest sub-item 5, and 
adding these up to generate a total between 0 and 15. 
 
  
Commento [MC4]: I would 
asterisk this and state that the 
evidence includes the overlapping 
syndrome of gastroparesis given 
the difficulty differentiating the two 
on clinical grounds 
Commento [LVO5]: This would 
indeed probably clarify things, 
especially for a US readership. 
Commento [QEM6]: Agree 
Commento [MS7]: I think the 
evidence from several studies 
demonstrating meal-induced increase 
in colorectal hypersensitivity and a 
parallel increase in symptom reporting 
(i.e. symptom reports at lower 
distention pressures and increased 
intensity) is sufficient evidence to 
increase this to B, in line with the 
evidence behind “B” for the FD-
pathophysiology-associations. The 
findings from existing studies are quite 
convincing and congruent. 
HT: Agree with Magnus comment on 
this 
Commento [LVO8]: I agree with 
Magnus and Hans here. 
Commento [MC9]: Jan, ...
Commento [MS10]: I disagree; 
there are indeed studies showing no ...
Commento [LVO11]: Agree with 
Magnus 
Commento [QEM12]: I agree with a 
C 
Commento [MC13]: Jan, I disagree 
with this appraisal  and with the ...
Commento [MS15]: I agree with C 
Commento [QEM14]: C for me. 
Commento [LVO16]: Would go for 
C too. 
Commento [MS17]: I would argue 
that there should be a “C” here, since ...
Commento [LVO18]: I see the point 
of Magnus, but find it hard to use the ...
Commento [MC19]: Jan, I perceive 
that the studies by Corinaldesi PMID: ...
Commento [MS20]: …but in most 
studies sx improvement does not ...
Commento [LVO21]: Agree with 
Magnus, I think our meta-analytical ...
Commento [MC22]: If you agree 
with my appraisals, this number would ...
Commento [MS23]: My suggested 
changes would increase this to 8, ...
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